RSS feed |
|
|
||||||
|
||||||
 |
||||||
|
||||||
| Procedural steps taken and scientific information after authorisation | ||||||
|
||||||
| EN | ||||||
|
|
|||||
List of major and/or minor changes and summaries after the authorisation |
||||||
|
||||||
| Detailed Summaries | ||||||
Detailed summaries are available in case of a major change to the use of the medicinal product e.g. a new indication. These summaries reflect the Scientific Discussion and conclusion by the EMEA scientific committee (CHMP) on a major change to a product after its initial marketing authorisation. |
||||||
|
|
|||||
| u | Plavix-H-C-174-II-61 Scientific Discussion | |||||
| u | Plavix-H-C-174-II-51 Scientific Discussion | |||||
|
||||||
Click here for the main report page
| |
|
EPARs for authorised medicinal products for human use |